View Future GrowthTherapeuticsMD 過去の業績過去 基準チェック /26TherapeuticsMDは、平均年間74.4%の収益成長を遂げていますが、 Pharmaceuticals業界の収益は、年間 成長しています。収益は、平均年間9.7% 32%収益成長率で 減少しています。 TherapeuticsMDの自己資本利益率は0.3%であり、純利益率は2.6%です。主要情報74.42%収益成長率80.64%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率-31.99%株主資本利益率0.32%ネット・マージン2.56%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Mar 31Full year 2025 earnings released: US$0.056 loss per share (vs US$0.20 loss in FY 2024)Full year 2025 results: US$0.056 loss per share (improved from US$0.20 loss in FY 2024). Revenue: US$3.02m (up 72% from FY 2024). Net loss: US$653.0k (loss narrowed 72% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: US$0.004 (vs US$0.049 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.004 (up from US$0.049 loss in 3Q 2024). Revenue: US$784.0k (up 43% from 3Q 2024). Net income: US$50.0k (up US$617.0k from 3Q 2024). Profit margin: 6.4% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 18Second quarter 2025 earnings released: EPS: US$0.047 (vs US$0.091 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.047 (up from US$0.091 loss in 2Q 2024). Net income: US$545.0k (up US$1.60m from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 15First quarter 2025 earnings released: US$0.055 loss per share (vs US$0.07 loss in 1Q 2024)First quarter 2025 results: US$0.055 loss per share (improved from US$0.07 loss in 1Q 2024). Net loss: US$636.0k (loss narrowed 21% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 28Full year 2024 earnings released: US$0.20 loss per share (vs US$0.74 loss in FY 2023)Full year 2024 results: US$0.20 loss per share (improved from US$0.74 loss in FY 2023). Net loss: US$2.31m (loss narrowed 70% from FY 2023).Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)Third quarter 2024 results: US$0.049 loss per share (improved from US$0.13 loss in 3Q 2023). Net loss: US$567.0k (loss narrowed 61% from 3Q 2023).すべての更新を表示Recent updatesお知らせ • Apr 02TherapeuticsMD, Inc. announced delayed annual 10-K filingOn 04/01/2026, TherapeuticsMD, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Reported Earnings • Mar 31Full year 2025 earnings released: US$0.056 loss per share (vs US$0.20 loss in FY 2024)Full year 2025 results: US$0.056 loss per share (improved from US$0.20 loss in FY 2024). Revenue: US$3.02m (up 72% from FY 2024). Net loss: US$653.0k (loss narrowed 72% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.New Risk • Jan 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (US$25.9m market cap).Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: US$0.004 (vs US$0.049 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.004 (up from US$0.049 loss in 3Q 2024). Revenue: US$784.0k (up 43% from 3Q 2024). Net income: US$50.0k (up US$617.0k from 3Q 2024). Profit margin: 6.4% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.お知らせ • Nov 04TherapeuticsMD, Inc., Annual General Meeting, Dec 15, 2025TherapeuticsMD, Inc., Annual General Meeting, Dec 15, 2025.Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Justin Roberts was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 18Second quarter 2025 earnings released: EPS: US$0.047 (vs US$0.091 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.047 (up from US$0.091 loss in 2Q 2024). Net income: US$545.0k (up US$1.60m from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.お知らせ • Jun 03Mayne Pharma LLC Provides Update on Legal Proceeding with TherapeuticsMD, IncMayne Pharma Group Limited announced that one of its US subsidiaries, Mayne Pharma LLC, has filed a complaint in the United States District Court for the District of Delaware against TherapeuticsMD, Inc. This complaint is related to the legal proceeding brought by TXMD which was previously disclosed in Mayne Pharma's ASX announcement on 11 April 2025. Mayne Pharma's complaint asserts claims against TXMD for breach of contract and fraud based on allegations that TXMD concealed information about certain commercialisation assets it sold to Mayne Pharma on 4 December 2022. Mayne Pharma is seeking more than $11.5 million in damages it incurred as a result of TXMD's alleged misrepresentations about the assets. In addition to filing a complaint against TXMD, Mayne Pharma has filed a motion to dismiss TXMD's proceeding in its entirety. Mayne Pharma emphatically denies any and all allegations of wrongdoing and believes TXMD's proceeding to be without merit, but there is no assurance that Mayne Pharma would be successful in any defence thereof.Reported Earnings • May 15First quarter 2025 earnings released: US$0.055 loss per share (vs US$0.07 loss in 1Q 2024)First quarter 2025 results: US$0.055 loss per share (improved from US$0.07 loss in 1Q 2024). Net loss: US$636.0k (loss narrowed 21% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 28Full year 2024 earnings released: US$0.20 loss per share (vs US$0.74 loss in FY 2023)Full year 2024 results: US$0.20 loss per share (improved from US$0.74 loss in FY 2023). Net loss: US$2.31m (loss narrowed 70% from FY 2023).New Risk • Feb 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.86m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Market cap is less than US$10m (US$9.86m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue).New Risk • Jan 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (US$9.92m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue).New Risk • Jan 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.92m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$9.92m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue).Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)Third quarter 2024 results: US$0.049 loss per share (improved from US$0.13 loss in 3Q 2023). Net loss: US$567.0k (loss narrowed 61% from 3Q 2023).お知らせ • Sep 23TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024.Reported Earnings • Aug 14Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)Second quarter 2024 results: US$0.091 loss per share (improved from US$0.24 loss in 2Q 2023). Net loss: US$1.05m (loss narrowed 56% from 2Q 2023).お知らせ • Aug 19TherapeuticsMD, Inc. Announces Executive ChangesTherapeuticsMD, Inc. announced that on August 17, 2023, Mr. Michael C. Donegan, the Principal Financial and Accounting Officer of the company, notified the Company of his decision to resign from such positions, effective as of August 17, 2023. Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the effective date of Mr. Donegan’s resignation. Mr. Ziegler, age 50, has served as founder and chief executive officer of JZ Advisory Group, a consulting company largely focused on providing fractional CFO and outsourced accounting services to middle-market and entrepreneurial businesses, since January 2022. He previously served as the Chief Financial Officer of DAS Health, a private equity owned provider of IT Services to healthcare providers, from April 2021 to December 2021 and as the Chief Financial Officer of Encompass Onsite, a provider of end-to-end property solutions, from November 2018 to February 2021. Prior to joining Encompass, he held multiple roles as a CFO in the healthcare industry, including private equity backed specialty pharmacy Biomatrix and Novis Pharmaceuticals. Mr. Ziegler has been a director of Progressive Care Inc. since December 2021. He earned his B.S. in Finance and an M.B.A. from Florida Atlantic University.お知らせ • May 19TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023, at 08:00 US Eastern Standard Time. Agenda: To consider and discuss the election of directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified; to approve the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2022; to approve an amendment to increase the number of authorized shares of common stock; to approve the issuance of up to 5,000,000 shares of the Company’s common stock to be sold in one or more private placements to Rubric Capital Management LP or one or more of its affiliates, under a subscription agreement with Rubric; to ratify the appointment of Grant Thornton LLP as the independent auditor of Company for the fiscal year ending December 31, 2023; and to discuss other business matters.お知らせ • Jan 07+ 1 more updateTherapeuticsMd, Inc. Announces Executive ChangesTherapeuticsMD, Inc. announced that On December 30, 2022 the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers. On January 4, 2023, the Board appointed Mr. Marlan Walker, the Company’s General Counsel, as the Company’s Chief Executive Officer and Principal Executive Officer.Seeking Alpha • Oct 03TherapeuticsMD raises $7M in private placementTherapeuticsMD (NASDAQ:TXMD) has received a $7M private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital. Under the terms of the Company’s financing agreement with its lender, Sixth Street Specialty Lending, upon receipt of the investment and the delivery to Sixth Street of warrants to acquire 125,000 shares of the Company’s common stock at an exercise price of $0.01 per share, the maturity date of the financing agreement was automatically extended until October 31, 2022. The Company has the option to further extend the maturity date until November 30, 2022, if it receives additional equity capital of $7 million. Source: Press ReleaseSeeking Alpha • Sep 12TherapeuticsMD appoints interim co-CEOsTherapeuticsMD (NASDAQ:TXMD) appointed Brian Bernick and Mark Glickman as interim co-CEO and co-principal executive officers. Bernick and Glickman succeed Hugh O’Dowd as CEO, the company said in a Sept. 12 press release. Prior to this appointment, Bernick, the company's co-founder, served as chief scientific and medical officer, and Glickman served as chief business officer. TherapeuticsMD also appointed Tommy Thompson, who served as chairman since 2012, as the executive chairman of the Board.Seeking Alpha • Aug 12Therapeutics MD Q2 Earnings PreviewTherapeutics MD (NASDAQ:TXMD) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$3.04 (-2663.6% Y/Y) and the consensus Revenue Estimate is $23.2M (+0.9% Y/Y). Over the last 1 year, TXMD has beaten EPS estimates 25% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revision and 0 downward. Revenue estimates have seen 0 upward revision and 1 downward.Seeking Alpha • Aug 01TherapeuticsMD receives $15M equity investment from Rubric CapitalTherapeuticsMD (NASDAQ:TXMD) received a $15M private investment in its common stock and a new series of preferred stock PIPE from Rubric Capital Management. Proceeds to be used for fulfilling its near-term operating capital requirements. In exchange for its initial $15M investment, Rubric received 565K shares of TherapeuticsMD common stock and 15K shares of newly designated Series A Preferred Stock, with a liquidation value of $1,333/share. Post transaction closure, Rubric will own ~18.3% of stock. The company also entered into an amendment with its lender, Sixth Street Specialty Lending, to extend the maturity date of of its financing agreement debt to Sep.30, 2022. The company also granted Sixth Street warrants to acquire 200K shares at an exercise price of $0.01 and would grant 125K additional common stock warrants for each additional monthly extension. It also has the option to further extend the maturity date until Oct. 31, 2022 and Nov. 30, 2022 if it receives additional equity capital of $7M per extension.Seeking Alpha • Jul 19TherapeuticsMD jumps 12% as top investor discloses insider purchaseThe shares of the women’s healthcare company TherapeuticsMD (NASDAQ:TXMD) surged ~12% on Tuesday after one of its leading institutional holders, Rubric Capital Management, announced the purchase of approximately 82.6K of company shares. The hedge fund, which had over 10% of company ownership, bought the shares on Friday and Monday at $5.56 and $6.03 apiece. The transactions valued at $467.4K have increased its holding by ~4%. Tuesday’s disclosure on the insider transactions comes days after TherapeuticsMD (TXMD) terminated its merger agreement with Athene Merger, an affiliate of EW Healthcare Partners. The deal fell apart after Athene failed to acquire the required number of TXMD shares during the tender offer, which the private equity firm previously extended, noting that TherapeuticsMD (TXMD) risked bankruptcy without the closure of the deal.Seeking Alpha • Jul 13TherapeuticsMD plunges 42% as merger agreement endsThe shares of TherapeuticsMD (NASDAQ:TXMD) dropped ~42% in the pre-market Wednesday after the women’s healthcare company announced the termination of its merger agreement with an Athene Merger, an affiliate of the private equity firm EW Healthcare Partners. The termination of the deal comes after Athene failed to acquire the required number of TXMD shares during an extended period of tender offer that ended on July 12. The end of the merger agreement is expected to take effect from July 13. Announcing the extension of the tender offer, EW Healthcare said last week that TherapeuticsMD (TXMD) risks bankruptcy without the closure of the merger deal. As of July 05, more than 2.5M TXMD shares or about ~29% of the company’s issued and outstanding shares, had been tendered.Seeking Alpha • Jul 06TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisitionPrivate equity firm EW Healthcare Partners announced on Wednesday that its affiliate Athene Merger extended the tender offer to acquire the women’s healthcare company TherapeuticsMD (NASDAQ:TXMD). Without a successful closure of the transaction, TherapeuticsMD (TXMD) will likely need to file for protection under Chapter 11, EW Healthcare reiterated. Per the revised terms, Athene Merger has extended the expiration date of its tender offer to July 12, 2022. As of July 05, more than 2.5M shares of TXMD, about ~29% of the issued and outstanding shares, had been tendered following the buyout offer. In May, TherapeuticsMD (TXMD) agreed to be acquired by an affiliate of EW Healthcare for $10 per share in an all-cash transaction. Previously, the parties expected to close the transaction before July 13.Seeking Alpha • Jun 16TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder PushbackTherapeuticsMD’s $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a standalone company in the long run. Shareholders were informed of a 50:1 reverse stock split at the end of Q1 2021 just a few days before the buyout was announced. Investors are in support of the acquisition due to TherapeuticsMD's poor financial position but insist on better terms including an expanded bidding process.Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$114.0m to US$111.0m. 2022 losses expected to reduce from -US$32.50 to -US$7.50 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$87.50 to US$2.50. Share price fell 18% to US$2.56 over the past week.Major Estimate Revision • May 07Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.16 to -US$0.65 per share. Revenue forecast of US$113.9m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 4.8% next year. Consensus price target down from US$4.17 to US$1.75. Share price fell 24% to US$0.15 over the past week.Price Target Changed • May 06Price target decreased to US$3.75Down from US$4.33, the current price target is an average from 3 analysts. New target price is 2,346% above last closing price of US$0.15. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.43 last year.Recent Insider Transactions Derivative • Apr 28Co-Founder notifies of intention to sell stockRobert Finizio intends to sell 10m shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of April. If the sale is conducted around the recent share price of US$0.24, it would amount to US$2.4m. Since June 2021, Robert has owned 19.99m shares directly. Company insiders have collectively bought US$1.1m more than they sold, via options and on-market transactions, in the last 12 months.Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 3 analysts covering TherapeuticsMD previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 88% per year to 2023. The company is expected to make a profit of US$43.7m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Recent Insider Transactions Derivative • Mar 22Co-Founder notifies of intention to sell stockRobert Finizio intends to sell 5m shares in the next 90 days after lodging an Intent To Sell Form on the 17th of March. If the sale is conducted around the recent share price of US$0.36, it would amount to US$1.8m. Since March 2021, Robert's direct individual holding has increased from 19.90m shares to 19.99m. Company insiders have collectively bought US$1.1m more than they sold, via options and on-market transactions, in the last 12 months.Major Estimate Revision • Mar 17Consensus revenue estimates fall by 24%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$150.4m to US$114.0m. Forecast losses increased from -US$0.15 to -US$0.16 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$4.33 to US$4.17. Share price fell 8.8% to US$0.36 over the past week.Seeking Alpha • Mar 14TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare BusinessTherapeuticsMD had a rough 2021, and the share price shows it. The company battled the COVID-19 headwinds and has struggled to expand ANNOVERA’s manufacturing. TherapeuticsMD has an imposing product portfolio. Sadly, the company’s products have struggled to gain traction on the market, and the earnings show it. TherapeuticsMD is selling their vitaCare prescription health business to GoodRx for $150M in cash, with an extra $7M in contingent. The company can pay off some of their debt. I believe there is a chance we finally see a turnaround for TXMD. I discuss my plan for managing my position. I have the buy target at $0.35 with Sell 1 at $0.67 and Sell 2 at $1.49. I do have a Sell 3 at $2.14, however, I am probably going to have to adjust that in the coming weeks as the chart’s technicals change.Breakeven Date Change • Mar 13Forecast breakeven date pushed back to 2024The 3 analysts covering TherapeuticsMD previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 88% per year to 2023. The company is expected to make a profit of US$43.7m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule.Reported Earnings • Mar 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.43 loss per share (up from US$0.67 loss in FY 2020). Revenue: US$87.0m (up 34% from FY 2020). Net loss: US$172.4m (loss narrowed 6.1% from FY 2020). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 73%, compared to a 20% growth forecast for the pharmaceuticals industry in the US.Recent Insider Transactions • Nov 24Independent Director recently bought US$579k worth of stockOn the 18th of November, Cooper Collins bought around 1m shares on-market at roughly US$0.58 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$1.4m more in shares than they have sold in the last 12 months.Reported Earnings • Nov 13Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$25.4m (up 31% from 3Q 2020). Net loss: US$47.4m (loss widened 45% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.Breakeven Date Change • Nov 13Forecast to breakeven in 2023The 4 analysts covering TherapeuticsMD expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$18.9m in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule.Seeking Alpha • Oct 22TherapeuticsMD: Time For Bulls To Take A Contrarian ApproachDespite having an impressive product portfolio and established commercial organization, the company has struggled to get their products off the launchpad and through COVID-19 headwinds. Earnings have been lackluster while the cash burn continues to incinerate their cash position. Accordingly, the share price has been pummeled to all-time lows along with investor sentiment. I still have a long-term bullish outlook in anticipation the company is able to weather the COVID-19 headwinds and record significant growth in the coming years. I reveal my strategy for changing my position from a dark red to a bright green.Executive Departure • Oct 06Executive Vice President of Operations Edward Borkowski has left the companyOn the 30th of September, Edward Borkowski's tenure as Executive Vice President of Operations ended after 1.7 years in the role. As of June 2021, Edward still personally held 59.25k shares (US$71k worth at the time). Edward is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.67 years.Recent Insider Transactions • Aug 20Independent Director recently bought US$725k worth of stockOn the 18th of August, Cooper Collins bought around 1m shares on-market at roughly US$0.72 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$804k more in shares than they have sold in the last 12 months.Reported Earnings • Aug 05Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$23.0m (up 115% from 2Q 2020). Net loss: US$42.7m (loss narrowed 18% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Breakeven Date Change • Aug 05No longer forecast to breakevenThe 4 analysts covering TherapeuticsMD no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$45.5m in 2023. New consensus forecast suggests the company will make a loss of US$10.1m in 2023.Seeking Alpha • Jul 08TherapeuticsMD: The Long Road To ProfitabilityAlthough the market did not take favorably to recent Q1 numbers, there were some encouraging trends. ANNOVERA continues to execute as marketing strategies continue to build awareness. Costs came down significantly in Q1 and sales grew by over 60%. We need more of the same going forward.Recent Insider Transactions Derivative • May 15Co-Founder exercised options and sold US$70k worth of stockOn the 11th of May, Robert Finizio exercised options to acquire 68k shares at no cost and sold these for an average price of US$1.04 per share. This trade did not impact their existing holding. For the year to December 2020, Robert's total compensation was 22% salary and 78% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2020, Robert's direct individual holding has decreased from 20.40m shares to 19.90m. Company insiders have collectively bought US$85k more than they sold, via options and on-market transactions, in the last 12 months.Reported Earnings • May 06First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$19.9m (up 62% from 1Q 2020). Net loss: US$39.4m (loss narrowed 31% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.Analyst Estimate Surprise Post Earnings • Mar 04Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Over the next year, revenue is forecast to grow 59%, compared to a 27% growth forecast for the Pharmaceuticals industry in the US.Reported Earnings • Mar 04Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$64.9m (up 31% from FY 2019). Net loss: US$183.5m (loss widened 4.2% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.分析記事 • Feb 24TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?TherapeuticsMD, Inc. ( NASDAQ:TXMD ) is possibly approaching a major achievement in its business, so we would like to...Price Target Changed • Feb 04Price target raised to US$8.00Up from US$6.40, the current price target is an average from 6 analysts. The new target price is 373% above the current share price of US$1.69. As of last close, the stock is down 34% over the past year.分析記事 • Jan 29TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To BeThe analysts covering TherapeuticsMD, Inc. ( NASDAQ:TXMD ) delivered a dose of negativity to shareholders today, by...分析記事 • Jan 27What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?Every investor in TherapeuticsMD, Inc. ( NASDAQ:TXMD ) should be aware of the most powerful shareholder groups...Is New 90 Day High Low • Jan 26New 90-day high: US$1.61The company is up 17% from its price of US$1.38 on 27 October 2020. The American market is also up 17% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$25.24 per share.分析記事 • Dec 30Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...分析記事 • Dec 09TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five YearsLong term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...Is New 90 Day High Low • Dec 09New 90-day low: US$1.21The company is down 10.0% from its price of US$1.34 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$20.91 per share.Price Target Changed • Dec 06Price target raised to US$8.20Up from US$7.28, the current price target is an average from 8 analysts. The new target price is 521% above the current share price of US$1.32. As of last close, the stock is down 46% over the past year.Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 126%, compared to a 22% growth forecast for the Pharmaceuticals industry in the US.Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.12 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$19.3m (down 19% from 3Q 2019). Net loss: US$32.6m (loss widened 2.0% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.Is New 90 Day High Low • Oct 31New 90-day low: US$1.22The company is down 34% from its price of US$1.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$9.19 per share.収支内訳TherapeuticsMD の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGS:TXMD 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 26305031 Dec 253-15030 Sep 25304030 Jun 253-14031 Mar 252-25031 Dec 242-25030 Sep 242-45030 Jun 241-56031 Mar 241-67031 Dec 231-89030 Sep 23694218030 Jun 23702930031 Mar 23701742031 Dec 2270157030 Sep 22-643-26-630 Jun 22-39-3010-431 Mar 22-17-5848-231 Dec 213-7973030 Sep 2191-172194830 Jun 2185-157182831 Mar 2172-166178931 Dec 2065-1841931030 Sep 2058-1911981230 Jun 2063-1902041531 Mar 2058-1931961731 Dec 1950-1761752030 Sep 1939-1661572230 Jun 1919-1701422531 Mar 1916-1481302731 Dec 1816-1331162730 Sep 1815-115953230 Jun 1816-94763131 Mar 1817-80623331 Dec 1717-77583430 Sep 1717-78603330 Jun 1718-89634131 Mar 1718-90594731 Dec 1619-90515430 Sep 1620-85445730 Jun 1620-79365931 Mar 1621-85326931 Dec 1520-85297230 Sep 1519-84267330 Jun 1518-822571質の高い収益: TXMDには$88.0K } という大きな 一回限りの 損失があり、過去 12 か月の財務実績が31st March, 2026に影響を及ぼしています。利益率の向上: TXMD過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: TXMD過去 5 年間で収益を上げており、収益は年間74.4%増加しています。成長の加速: TXMDは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: TXMD昨年収益を上げたため、昨年の収益成長をPharmaceuticals業界 ( -5% ) と比較することは困難です。株主資本利益率高いROE: TXMDの 自己資本利益率 ( 0.3% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 21:58終値2026/05/21 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋TherapeuticsMD, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。17 アナリスト機関John TannerCantor Fitzgerald & Co.Oren LivnatCitizens JMP Securities, LLCRobert LabickCJS Securities, Inc.14 その他のアナリストを表示
Reported Earnings • Mar 31Full year 2025 earnings released: US$0.056 loss per share (vs US$0.20 loss in FY 2024)Full year 2025 results: US$0.056 loss per share (improved from US$0.20 loss in FY 2024). Revenue: US$3.02m (up 72% from FY 2024). Net loss: US$653.0k (loss narrowed 72% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: US$0.004 (vs US$0.049 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.004 (up from US$0.049 loss in 3Q 2024). Revenue: US$784.0k (up 43% from 3Q 2024). Net income: US$50.0k (up US$617.0k from 3Q 2024). Profit margin: 6.4% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 18Second quarter 2025 earnings released: EPS: US$0.047 (vs US$0.091 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.047 (up from US$0.091 loss in 2Q 2024). Net income: US$545.0k (up US$1.60m from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 15First quarter 2025 earnings released: US$0.055 loss per share (vs US$0.07 loss in 1Q 2024)First quarter 2025 results: US$0.055 loss per share (improved from US$0.07 loss in 1Q 2024). Net loss: US$636.0k (loss narrowed 21% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 28Full year 2024 earnings released: US$0.20 loss per share (vs US$0.74 loss in FY 2023)Full year 2024 results: US$0.20 loss per share (improved from US$0.74 loss in FY 2023). Net loss: US$2.31m (loss narrowed 70% from FY 2023).
Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)Third quarter 2024 results: US$0.049 loss per share (improved from US$0.13 loss in 3Q 2023). Net loss: US$567.0k (loss narrowed 61% from 3Q 2023).
お知らせ • Apr 02TherapeuticsMD, Inc. announced delayed annual 10-K filingOn 04/01/2026, TherapeuticsMD, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Reported Earnings • Mar 31Full year 2025 earnings released: US$0.056 loss per share (vs US$0.20 loss in FY 2024)Full year 2025 results: US$0.056 loss per share (improved from US$0.20 loss in FY 2024). Revenue: US$3.02m (up 72% from FY 2024). Net loss: US$653.0k (loss narrowed 72% from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 65 percentage points per year, which is a significant difference in performance.
New Risk • Jan 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Large one-off items impacting financial results. Revenue is less than US$5m (US$2.8m revenue). Market cap is less than US$100m (US$25.9m market cap).
Reported Earnings • Nov 14Third quarter 2025 earnings released: EPS: US$0.004 (vs US$0.049 loss in 3Q 2024)Third quarter 2025 results: EPS: US$0.004 (up from US$0.049 loss in 3Q 2024). Revenue: US$784.0k (up 43% from 3Q 2024). Net income: US$50.0k (up US$617.0k from 3Q 2024). Profit margin: 6.4% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 42 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 04TherapeuticsMD, Inc., Annual General Meeting, Dec 15, 2025TherapeuticsMD, Inc., Annual General Meeting, Dec 15, 2025.
Board Change • Sep 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Director Justin Roberts was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 18Second quarter 2025 earnings released: EPS: US$0.047 (vs US$0.091 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.047 (up from US$0.091 loss in 2Q 2024). Net income: US$545.0k (up US$1.60m from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 50% per year, which means it is performing significantly worse than earnings.
お知らせ • Jun 03Mayne Pharma LLC Provides Update on Legal Proceeding with TherapeuticsMD, IncMayne Pharma Group Limited announced that one of its US subsidiaries, Mayne Pharma LLC, has filed a complaint in the United States District Court for the District of Delaware against TherapeuticsMD, Inc. This complaint is related to the legal proceeding brought by TXMD which was previously disclosed in Mayne Pharma's ASX announcement on 11 April 2025. Mayne Pharma's complaint asserts claims against TXMD for breach of contract and fraud based on allegations that TXMD concealed information about certain commercialisation assets it sold to Mayne Pharma on 4 December 2022. Mayne Pharma is seeking more than $11.5 million in damages it incurred as a result of TXMD's alleged misrepresentations about the assets. In addition to filing a complaint against TXMD, Mayne Pharma has filed a motion to dismiss TXMD's proceeding in its entirety. Mayne Pharma emphatically denies any and all allegations of wrongdoing and believes TXMD's proceeding to be without merit, but there is no assurance that Mayne Pharma would be successful in any defence thereof.
Reported Earnings • May 15First quarter 2025 earnings released: US$0.055 loss per share (vs US$0.07 loss in 1Q 2024)First quarter 2025 results: US$0.055 loss per share (improved from US$0.07 loss in 1Q 2024). Net loss: US$636.0k (loss narrowed 21% from 1Q 2024). Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 28Full year 2024 earnings released: US$0.20 loss per share (vs US$0.74 loss in FY 2023)Full year 2024 results: US$0.20 loss per share (improved from US$0.74 loss in FY 2023). Net loss: US$2.31m (loss narrowed 70% from FY 2023).
New Risk • Feb 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.86m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (29% average weekly change). Market cap is less than US$10m (US$9.86m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue).
New Risk • Jan 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 24% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (24% average weekly change). Market cap is less than US$10m (US$9.92m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue).
New Risk • Jan 02New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: US$9.92m This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (US$9.92m market cap). Minor Risk Revenue is less than US$5m (US$1.6m revenue).
Reported Earnings • Nov 14Third quarter 2024 earnings released: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023)Third quarter 2024 results: US$0.049 loss per share (improved from US$0.13 loss in 3Q 2023). Net loss: US$567.0k (loss narrowed 61% from 3Q 2023).
お知らせ • Sep 23TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024TherapeuticsMD, Inc., Annual General Meeting, Dec 05, 2024.
Reported Earnings • Aug 14Second quarter 2024 earnings released: US$0.091 loss per share (vs US$0.24 loss in 2Q 2023)Second quarter 2024 results: US$0.091 loss per share (improved from US$0.24 loss in 2Q 2023). Net loss: US$1.05m (loss narrowed 56% from 2Q 2023).
お知らせ • Aug 19TherapeuticsMD, Inc. Announces Executive ChangesTherapeuticsMD, Inc. announced that on August 17, 2023, Mr. Michael C. Donegan, the Principal Financial and Accounting Officer of the company, notified the Company of his decision to resign from such positions, effective as of August 17, 2023. Mr. Ziegler succeeded Mr. Donegan as Principal Financial and Accounting Officer as of the effective date of Mr. Donegan’s resignation. Mr. Ziegler, age 50, has served as founder and chief executive officer of JZ Advisory Group, a consulting company largely focused on providing fractional CFO and outsourced accounting services to middle-market and entrepreneurial businesses, since January 2022. He previously served as the Chief Financial Officer of DAS Health, a private equity owned provider of IT Services to healthcare providers, from April 2021 to December 2021 and as the Chief Financial Officer of Encompass Onsite, a provider of end-to-end property solutions, from November 2018 to February 2021. Prior to joining Encompass, he held multiple roles as a CFO in the healthcare industry, including private equity backed specialty pharmacy Biomatrix and Novis Pharmaceuticals. Mr. Ziegler has been a director of Progressive Care Inc. since December 2021. He earned his B.S. in Finance and an M.B.A. from Florida Atlantic University.
お知らせ • May 19TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023TherapeuticsMD, Inc., Annual General Meeting, Jun 26, 2023, at 08:00 US Eastern Standard Time. Agenda: To consider and discuss the election of directors to serve until our next annual meeting of stockholders or until their successors are duly elected and qualified; to approve the compensation of the Company’s named executive officers for the fiscal year ended December 31, 2022; to approve an amendment to increase the number of authorized shares of common stock; to approve the issuance of up to 5,000,000 shares of the Company’s common stock to be sold in one or more private placements to Rubric Capital Management LP or one or more of its affiliates, under a subscription agreement with Rubric; to ratify the appointment of Grant Thornton LLP as the independent auditor of Company for the fiscal year ending December 31, 2023; and to discuss other business matters.
お知らせ • Jan 07+ 1 more updateTherapeuticsMd, Inc. Announces Executive ChangesTherapeuticsMD, Inc. announced that On December 30, 2022 the Company terminated Dr. Brian Bernick and Mr. Mark Glickman as the Company’s Interim Co-Chief Executive Officers and Principal Executive Officers. On January 4, 2023, the Board appointed Mr. Marlan Walker, the Company’s General Counsel, as the Company’s Chief Executive Officer and Principal Executive Officer.
Seeking Alpha • Oct 03TherapeuticsMD raises $7M in private placementTherapeuticsMD (NASDAQ:TXMD) has received a $7M private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital. Under the terms of the Company’s financing agreement with its lender, Sixth Street Specialty Lending, upon receipt of the investment and the delivery to Sixth Street of warrants to acquire 125,000 shares of the Company’s common stock at an exercise price of $0.01 per share, the maturity date of the financing agreement was automatically extended until October 31, 2022. The Company has the option to further extend the maturity date until November 30, 2022, if it receives additional equity capital of $7 million. Source: Press Release
Seeking Alpha • Sep 12TherapeuticsMD appoints interim co-CEOsTherapeuticsMD (NASDAQ:TXMD) appointed Brian Bernick and Mark Glickman as interim co-CEO and co-principal executive officers. Bernick and Glickman succeed Hugh O’Dowd as CEO, the company said in a Sept. 12 press release. Prior to this appointment, Bernick, the company's co-founder, served as chief scientific and medical officer, and Glickman served as chief business officer. TherapeuticsMD also appointed Tommy Thompson, who served as chairman since 2012, as the executive chairman of the Board.
Seeking Alpha • Aug 12Therapeutics MD Q2 Earnings PreviewTherapeutics MD (NASDAQ:TXMD) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$3.04 (-2663.6% Y/Y) and the consensus Revenue Estimate is $23.2M (+0.9% Y/Y). Over the last 1 year, TXMD has beaten EPS estimates 25% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revision and 0 downward. Revenue estimates have seen 0 upward revision and 1 downward.
Seeking Alpha • Aug 01TherapeuticsMD receives $15M equity investment from Rubric CapitalTherapeuticsMD (NASDAQ:TXMD) received a $15M private investment in its common stock and a new series of preferred stock PIPE from Rubric Capital Management. Proceeds to be used for fulfilling its near-term operating capital requirements. In exchange for its initial $15M investment, Rubric received 565K shares of TherapeuticsMD common stock and 15K shares of newly designated Series A Preferred Stock, with a liquidation value of $1,333/share. Post transaction closure, Rubric will own ~18.3% of stock. The company also entered into an amendment with its lender, Sixth Street Specialty Lending, to extend the maturity date of of its financing agreement debt to Sep.30, 2022. The company also granted Sixth Street warrants to acquire 200K shares at an exercise price of $0.01 and would grant 125K additional common stock warrants for each additional monthly extension. It also has the option to further extend the maturity date until Oct. 31, 2022 and Nov. 30, 2022 if it receives additional equity capital of $7M per extension.
Seeking Alpha • Jul 19TherapeuticsMD jumps 12% as top investor discloses insider purchaseThe shares of the women’s healthcare company TherapeuticsMD (NASDAQ:TXMD) surged ~12% on Tuesday after one of its leading institutional holders, Rubric Capital Management, announced the purchase of approximately 82.6K of company shares. The hedge fund, which had over 10% of company ownership, bought the shares on Friday and Monday at $5.56 and $6.03 apiece. The transactions valued at $467.4K have increased its holding by ~4%. Tuesday’s disclosure on the insider transactions comes days after TherapeuticsMD (TXMD) terminated its merger agreement with Athene Merger, an affiliate of EW Healthcare Partners. The deal fell apart after Athene failed to acquire the required number of TXMD shares during the tender offer, which the private equity firm previously extended, noting that TherapeuticsMD (TXMD) risked bankruptcy without the closure of the deal.
Seeking Alpha • Jul 13TherapeuticsMD plunges 42% as merger agreement endsThe shares of TherapeuticsMD (NASDAQ:TXMD) dropped ~42% in the pre-market Wednesday after the women’s healthcare company announced the termination of its merger agreement with an Athene Merger, an affiliate of the private equity firm EW Healthcare Partners. The termination of the deal comes after Athene failed to acquire the required number of TXMD shares during an extended period of tender offer that ended on July 12. The end of the merger agreement is expected to take effect from July 13. Announcing the extension of the tender offer, EW Healthcare said last week that TherapeuticsMD (TXMD) risks bankruptcy without the closure of the merger deal. As of July 05, more than 2.5M TXMD shares or about ~29% of the company’s issued and outstanding shares, had been tendered.
Seeking Alpha • Jul 06TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisitionPrivate equity firm EW Healthcare Partners announced on Wednesday that its affiliate Athene Merger extended the tender offer to acquire the women’s healthcare company TherapeuticsMD (NASDAQ:TXMD). Without a successful closure of the transaction, TherapeuticsMD (TXMD) will likely need to file for protection under Chapter 11, EW Healthcare reiterated. Per the revised terms, Athene Merger has extended the expiration date of its tender offer to July 12, 2022. As of July 05, more than 2.5M shares of TXMD, about ~29% of the issued and outstanding shares, had been tendered following the buyout offer. In May, TherapeuticsMD (TXMD) agreed to be acquired by an affiliate of EW Healthcare for $10 per share in an all-cash transaction. Previously, the parties expected to close the transaction before July 13.
Seeking Alpha • Jun 16TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder PushbackTherapeuticsMD’s $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a standalone company in the long run. Shareholders were informed of a 50:1 reverse stock split at the end of Q1 2021 just a few days before the buyout was announced. Investors are in support of the acquisition due to TherapeuticsMD's poor financial position but insist on better terms including an expanded bidding process.
Major Estimate Revision • May 23Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$114.0m to US$111.0m. 2022 losses expected to reduce from -US$32.50 to -US$7.50 per share. Pharmaceuticals industry in the US expected to see average net income growth of 9.5% next year. Consensus price target down from US$87.50 to US$2.50. Share price fell 18% to US$2.56 over the past week.
Major Estimate Revision • May 07Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 expected loss increased from -US$0.16 to -US$0.65 per share. Revenue forecast of US$113.9m unchanged since last update. Pharmaceuticals industry in the US expected to see average net income growth of 4.8% next year. Consensus price target down from US$4.17 to US$1.75. Share price fell 24% to US$0.15 over the past week.
Price Target Changed • May 06Price target decreased to US$3.75Down from US$4.33, the current price target is an average from 3 analysts. New target price is 2,346% above last closing price of US$0.15. Stock is down 86% over the past year. The company is forecast to post a net loss per share of US$0.14 next year compared to a net loss per share of US$0.43 last year.
Recent Insider Transactions Derivative • Apr 28Co-Founder notifies of intention to sell stockRobert Finizio intends to sell 10m shares in the next 90 days after lodging an Intent To Sell Form on the 22nd of April. If the sale is conducted around the recent share price of US$0.24, it would amount to US$2.4m. Since June 2021, Robert has owned 19.99m shares directly. Company insiders have collectively bought US$1.1m more than they sold, via options and on-market transactions, in the last 12 months.
Breakeven Date Change • Apr 27Forecast breakeven date pushed back to 2024The 3 analysts covering TherapeuticsMD previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 88% per year to 2023. The company is expected to make a profit of US$43.7m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Recent Insider Transactions Derivative • Mar 22Co-Founder notifies of intention to sell stockRobert Finizio intends to sell 5m shares in the next 90 days after lodging an Intent To Sell Form on the 17th of March. If the sale is conducted around the recent share price of US$0.36, it would amount to US$1.8m. Since March 2021, Robert's direct individual holding has increased from 19.90m shares to 19.99m. Company insiders have collectively bought US$1.1m more than they sold, via options and on-market transactions, in the last 12 months.
Major Estimate Revision • Mar 17Consensus revenue estimates fall by 24%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from US$150.4m to US$114.0m. Forecast losses increased from -US$0.15 to -US$0.16 per share. Pharmaceuticals industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$4.33 to US$4.17. Share price fell 8.8% to US$0.36 over the past week.
Seeking Alpha • Mar 14TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare BusinessTherapeuticsMD had a rough 2021, and the share price shows it. The company battled the COVID-19 headwinds and has struggled to expand ANNOVERA’s manufacturing. TherapeuticsMD has an imposing product portfolio. Sadly, the company’s products have struggled to gain traction on the market, and the earnings show it. TherapeuticsMD is selling their vitaCare prescription health business to GoodRx for $150M in cash, with an extra $7M in contingent. The company can pay off some of their debt. I believe there is a chance we finally see a turnaround for TXMD. I discuss my plan for managing my position. I have the buy target at $0.35 with Sell 1 at $0.67 and Sell 2 at $1.49. I do have a Sell 3 at $2.14, however, I am probably going to have to adjust that in the coming weeks as the chart’s technicals change.
Breakeven Date Change • Mar 13Forecast breakeven date pushed back to 2024The 3 analysts covering TherapeuticsMD previously expected the company to break even in 2023. New consensus forecast suggests losses will reduce by 88% per year to 2023. The company is expected to make a profit of US$43.7m in 2024. Average annual earnings growth of 69% is required to achieve expected profit on schedule.
Reported Earnings • Mar 11Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: US$0.43 loss per share (up from US$0.67 loss in FY 2020). Revenue: US$87.0m (up 34% from FY 2020). Net loss: US$172.4m (loss narrowed 6.1% from FY 2020). Revenue missed analyst estimates by 11%. Earnings per share (EPS) exceeded analyst estimates by 6.6%. Over the next year, revenue is forecast to grow 73%, compared to a 20% growth forecast for the pharmaceuticals industry in the US.
Recent Insider Transactions • Nov 24Independent Director recently bought US$579k worth of stockOn the 18th of November, Cooper Collins bought around 1m shares on-market at roughly US$0.58 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$1.4m more in shares than they have sold in the last 12 months.
Reported Earnings • Nov 13Third quarter 2021 earnings released: US$0.11 loss per share (vs US$0.12 loss in 3Q 2020)The company reported a mediocre third quarter result with increased losses and weaker control over costs, although revenues improved. Third quarter 2021 results: Revenue: US$25.4m (up 31% from 3Q 2020). Net loss: US$47.4m (loss widened 45% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 49% per year, which means it is significantly lagging earnings.
Breakeven Date Change • Nov 13Forecast to breakeven in 2023The 4 analysts covering TherapeuticsMD expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$18.9m in 2023. Average annual earnings growth of 72% is required to achieve expected profit on schedule.
Seeking Alpha • Oct 22TherapeuticsMD: Time For Bulls To Take A Contrarian ApproachDespite having an impressive product portfolio and established commercial organization, the company has struggled to get their products off the launchpad and through COVID-19 headwinds. Earnings have been lackluster while the cash burn continues to incinerate their cash position. Accordingly, the share price has been pummeled to all-time lows along with investor sentiment. I still have a long-term bullish outlook in anticipation the company is able to weather the COVID-19 headwinds and record significant growth in the coming years. I reveal my strategy for changing my position from a dark red to a bright green.
Executive Departure • Oct 06Executive Vice President of Operations Edward Borkowski has left the companyOn the 30th of September, Edward Borkowski's tenure as Executive Vice President of Operations ended after 1.7 years in the role. As of June 2021, Edward still personally held 59.25k shares (US$71k worth at the time). Edward is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 2.67 years.
Recent Insider Transactions • Aug 20Independent Director recently bought US$725k worth of stockOn the 18th of August, Cooper Collins bought around 1m shares on-market at roughly US$0.72 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$804k more in shares than they have sold in the last 12 months.
Reported Earnings • Aug 05Second quarter 2021 earnings released: US$0.11 loss per share (vs US$0.19 loss in 2Q 2020)The company reported a solid second quarter result with reduced losses, improved revenues and improved control over expenses. Second quarter 2021 results: Revenue: US$23.0m (up 115% from 2Q 2020). Net loss: US$42.7m (loss narrowed 18% from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Breakeven Date Change • Aug 05No longer forecast to breakevenThe 4 analysts covering TherapeuticsMD no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$45.5m in 2023. New consensus forecast suggests the company will make a loss of US$10.1m in 2023.
Seeking Alpha • Jul 08TherapeuticsMD: The Long Road To ProfitabilityAlthough the market did not take favorably to recent Q1 numbers, there were some encouraging trends. ANNOVERA continues to execute as marketing strategies continue to build awareness. Costs came down significantly in Q1 and sales grew by over 60%. We need more of the same going forward.
Recent Insider Transactions Derivative • May 15Co-Founder exercised options and sold US$70k worth of stockOn the 11th of May, Robert Finizio exercised options to acquire 68k shares at no cost and sold these for an average price of US$1.04 per share. This trade did not impact their existing holding. For the year to December 2020, Robert's total compensation was 22% salary and 78% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since June 2020, Robert's direct individual holding has decreased from 20.40m shares to 19.90m. Company insiders have collectively bought US$85k more than they sold, via options and on-market transactions, in the last 12 months.
Reported Earnings • May 06First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.21 loss in 1Q 2020)The company reported a solid first quarter result with reduced losses, improved revenues and improved control over expenses. First quarter 2021 results: Revenue: US$19.9m (up 62% from 1Q 2020). Net loss: US$39.4m (loss narrowed 31% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 43% per year, which means it is performing significantly worse than earnings.
Analyst Estimate Surprise Post Earnings • Mar 04Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 2.4%. Earnings per share (EPS) also surpassed analyst estimates by 9.8%. Over the next year, revenue is forecast to grow 59%, compared to a 27% growth forecast for the Pharmaceuticals industry in the US.
Reported Earnings • Mar 04Full year 2020 earnings released: US$0.67 loss per share (vs US$0.71 loss in FY 2019)The company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$64.9m (up 31% from FY 2019). Net loss: US$183.5m (loss widened 4.2% from FY 2019). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
分析記事 • Feb 24TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?TherapeuticsMD, Inc. ( NASDAQ:TXMD ) is possibly approaching a major achievement in its business, so we would like to...
Price Target Changed • Feb 04Price target raised to US$8.00Up from US$6.40, the current price target is an average from 6 analysts. The new target price is 373% above the current share price of US$1.69. As of last close, the stock is down 34% over the past year.
分析記事 • Jan 29TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To BeThe analysts covering TherapeuticsMD, Inc. ( NASDAQ:TXMD ) delivered a dose of negativity to shareholders today, by...
分析記事 • Jan 27What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?Every investor in TherapeuticsMD, Inc. ( NASDAQ:TXMD ) should be aware of the most powerful shareholder groups...
Is New 90 Day High Low • Jan 26New 90-day high: US$1.61The company is up 17% from its price of US$1.38 on 27 October 2020. The American market is also up 17% over the last 90 days, indicating the company’s price trend is similar to the market over that time. However, it outperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$25.24 per share.
分析記事 • Dec 30Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
分析記事 • Dec 09TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five YearsLong term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...
Is New 90 Day High Low • Dec 09New 90-day low: US$1.21The company is down 10.0% from its price of US$1.34 on 09 September 2020. The American market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$20.91 per share.
Price Target Changed • Dec 06Price target raised to US$8.20Up from US$7.28, the current price target is an average from 8 analysts. The new target price is 521% above the current share price of US$1.32. As of last close, the stock is down 46% over the past year.
Analyst Estimate Surprise Post Earnings • Nov 11Revenue beats expectations, earnings disappointRevenue exceeded analyst estimates by 25%. Earnings per share (EPS) missed analyst estimates by 11%. Over the next year, revenue is forecast to grow 126%, compared to a 22% growth forecast for the Pharmaceuticals industry in the US.
Reported Earnings • Nov 11Third quarter 2020 earnings released: US$0.12 loss per shareThe company reported a poor third quarter result with increased losses and weaker revenues and control over expenses. Third quarter 2020 results: Revenue: US$19.3m (down 19% from 3Q 2019). Net loss: US$32.6m (loss widened 2.0% from 3Q 2019). Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 39% per year, which means it is performing significantly worse than earnings.
Is New 90 Day High Low • Oct 31New 90-day low: US$1.22The company is down 34% from its price of US$1.85 on 31 July 2020. The American market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$9.19 per share.